© 2020 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2020 MJH Life Sciences™ and OncLive. All rights reserved.
May 6th 2016
Graham Dixon, PhD, chief scientific officer, Onxeo, discusses a mechanistic study of the relative cytotoxicity of doxorubicin-loaded nanoparticle formulation versus doxorubicin in hepatocellular carcinoma cell lines.
February 13th 2016
Graham Dixon, PhD, chief scientific officer, Onxeo, director, R&D, Onxeo, discusses a phase I study investigating the combination of belinostat (Beleodaq) plus CHOP in patients with peripheral T-cell lymphoma.